地塞米松(Dexamethasone) - 药物靶点：GR_在研适应症：术后炎症，黄斑水肿，非感染性后葡萄膜炎_专利_临床

概要

基本信息

简介地塞米松是一种具有糖皮质激素受体 (GR) 激动作用的小分子药物。 GR 广泛分布于各种细胞类型，负责无数生理反应，包括免疫和炎症反应。地塞米松与 GR 结合，通过基因表达和蛋白质合成发挥激动作用，从而降低机体炎症反应，降低免疫系统活动。地塞米松已证明可以治疗多种疾病，包括但不限于光化性唇炎、轻链 (AL) 淀粉样变性、眼部炎症、黄斑水肿和过敏反应。早在 1958 年 10 月 30 日，FDA 就批准了地塞米松。此外，英国国家卫生服务局和美国国立卫生研究院推荐地塞米松用于需要机械通气或补充氧气（无通气）的COVID-19患者。

药物类型

小分子化药

别名

CMIO-DEX、Decadron Phosphate、Dexamethasone Intravitreal Implant

+ [50]

靶点

GR

作用方式

激动剂

作用机制

GR激动剂(糖皮质激素受体激动剂)

治疗领域

肿瘤免疫系统疾病感染+ [13]

在研适应症

术后炎症黄斑水肿非感染性后葡萄膜炎+ [75]

非在研适应症

急性外耳炎急性中耳炎淋巴母细胞淋巴瘤+ [74]

原研机构

在研机构

+ [36]

非在研机构

Otonomy, Inc.

Eli Lilly & Co.Allergan UC

+ [33]

权益机构

AcuCort ABAffaMed Therapeutics (HK) Ltd.

EyePoint, Inc.

+ [14]

最高研发阶段批准上市

首次获批日期

美国 (1958-10-30),

过敏反应内分泌系统疾病眼部疾病+ [7]

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C22H29FO5

InChIKeyUREBDLICKHMUKA-CXSFZGCWSA-N

CAS号50-02-2

关联

2,184

项与地塞米松相关的临床试验

NCT07600151

/ Not yet recruiting临床1/2期IIT

A Clinical Phase I/II, Multicenter, Open-label, National Study Evaluating Quintuplet Treat-ment With ISaTuximab, Bortezomib, Lenalidomide and Dexamethasone Plus Etentamig (Etenta-Isa-VRd) in Primary DiagnOsed High-Risk Multiple Myeloma Patients

This study is researching an experimental five-drug combination called etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) and high-risk disease who are eligible for autologous stem cell transplantation.

开始日期2026-12-01

申办/合作机构

Universitätsklinikum Hamburg-Eppendorf

[+2]

NCT07870278

/ Not yet recruiting临床1期

A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK-6255 Monotherapy in Advanced Solid Tumors

Researchers are looking for new ways to treat advanced and recurrent endometrial cancer (EC) and ovarian cancer (OC). Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Recurrent means the cancer came back after treatment.
MK-6255 is a trial medicine designed to treat advanced and recurrent EC and OC. This trial is the first time that researchers will give MK-6255 to people.
The goals of this trial are to learn about:
* The safety of MK-6255 and if participants tolerate it. Tolerate means participants will receive the trial medicine unless they need to stop it due to health problems.
* What happens to different dose levels (amounts) of MK-6255 in the body over time.

开始日期2026-11-13

申办/合作机构

Merck Sharp & Dohme LLC

NCT07837674

/ Not yet recruitingN/AIIT

Impact of Intravenous Dexamethasone on the Duration of Motor and Sensory Block Following Spinal Anesthesia With Chloroprocaine

The purpose of this study is to compare the effect of a single dose of 8 mg of intravenous dexamethasone versus placebo on the duration of sensory and motor block after spinal anesthesia with chloroprocaine.

开始日期2026-11-01

申办/合作机构-

100 项与地塞米松相关的临床结果

登录后查看更多信息

100 项与地塞米松相关的转化医学

登录后查看更多信息

100 项与地塞米松相关的专利（医药）

登录后查看更多信息

67,721

项与地塞米松相关的文献（医药）

2027-03-01·Value in Health Regional Issues

Cost-Minimization Analysis of Intravenous and Subcutaneous Daratumumab in Patients With Multiple Myeloma: A Societal and Healthcare System Perspective

Article

作者: Fantelli, Valentina ; Temporin, Francesca ; Venturini, Francesca ; Riccoboni, Debora ; Zambello, Renato ; Berti, Giacomo

OBJECTIVES:

We compared costs of daratumumab (DARA) subcutaneous (SC) versus intravenous (IV) from societal and healthcare system perspectives.

METHODS:

We performed a cost-minimization analysis over 24 months using real-world weight distribution data from 304 patients treated in 2024. IV drug costs were weighted by patient distribution across 14 weight categories (6.25 kg intervals). We analyzed 4 patient scenarios (employed/unemployed, with/without caregiver) and 2 regimens (DARA-lenalidomide-dexamethasone, DARA-bortezomib-dexamethasone). Costs included drug acquisition, preparation materials, personnel time, and productivity losses. Probabilistic sensitivity analysis (10 000 Monte Carlo simulations) assessed robustness to weight distribution uncertainty. Break-even analysis identified weight thresholds at which formulations were cost equivalent.

RESULTS:

Initial IV administration required 1104 minutes versus 22 minutes for SC; subsequent IV administrations required 392 minutes. Weighted average IV drug cost was €5579 versus €5652 for SC. From a societal perspective, SC generated savings of €1125 to €11 899 across all scenarios. Probabilistic analysis showed 100% probability of SC cost saving (mean €5839; 95% CI €2204-€14 317), with weight distribution uncertainty contributing only 2% of total cost variability. Break-even analysis showed IV was marginally cheaper only in patients < 68.75 kg (42.9% of cohort). From the healthcare provider perspective, SC generated higher net revenues (€308 versus €175 per administration); payer costs remained neutral (€315 per administration regardless of route).

CONCLUSIONS:

SC DARA provides robust economic advantages across all regimens, patient scenarios, and time horizons. Despite marginal cost advantages for IV in less weight patients, the comprehensive clinical and operational benefits strongly support SC as the preferred administration route.

2027-02-01·TISSUE & CELL

Shionone attenuates lipopolysaccharide-induced acute lung injury by inhibiting ferroptosis via Keap1/Nrf2/SLC7A11/GPX4 signaling pathway

Article

作者: Sun, Yang ; Han, Zhipeng ; Yuan, Peizhi ; Arad, Maor ; Zhong, Mengling ; Zhang, Tianyao ; Feng, Mingmei ; Chen, Jiaxi ; Zhang, Qi

Acute lung injury (ALI) is a respiratory disease with a high mortality rate. Shionone, derived from the Chinese herbal medicine Aster tataricus, has anti-inflammatory and antioxidant effects. However, its protective effect on ALI remains unclear. In this study, we aimed to assess the protective effect of shionone on lipopolysaccharide (LPS)-induced ALI and to elucidate its underlying mechanisms. In this study, male C57BL/6 mice aged 8-10 weeks were randomly divided into five groups (10 mice per group) including control group, LPS group, LPS + shionone (50 mg/kg) group, LPS + shionone (100 mg/kg) group, and LPS + Dexamethasone (1 mg/kg) group. In mice with LPS-induced ALI, shionone significantly reduced lung index, lung wet/dry weight ratio, production of inflammatory cytokines, nitric oxide (NO) content, malondialdehyde (MDA) production, and increased superoxide dismutase (SOD) activity and nicotinamide adenine dinucleotide phosphate (NADPH) level. Shionone improved lung histopathological injury by inhibiting inflammatory cell infiltration and edema in LPS-induced ALI in mice. In vitro, shionone inhibited oxidative stress and inflammation in LPS-induced BEAS-2B cells. Shionone improved the protein expression of anti-ferroptosis proteins, including glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11), in mice lung tissues and BEAS-2B cells. Additionally, GC-MS-based metabolomic analysis showed that shionone increased the levels of various metabolites, such as fructose, glucose, and lactic acid. Shionone ameliorated LPS-induced ALI by downregulating Kelch-like ECH-associated protein 1 (Keap1) and upregulating Nuclear factor erythroid 2-related factor 2 (Nrf2), Heme oxygenase-1 (HO-1), and quinone oxidoreductase 1 (NQO1) in both in vivo and in vitro study. In conclusion, this study demonstrated that shionone mitigated LPS-induced ALI by inhibiting ferroptosis through regulation of Keap1/Nrf2/SLC7A11/GPX4 pathway, indicating that shionone may be a promising agent for ALI.

2027-02-01·JOURNAL OF ETHNOPHARMACOLOGY

Ainsliaea fragrans Champ. alleviates endometritis by modulating the STING-TBK1-IRF3 and NLRP3 inflammasome signaling pathway

Article

作者: Wu, Yanyu ; Lui, Jun ; Fu, Wenyan ; Zhuang, Yuan ; Cheng, Yufen

ETHNOPHARMACOLOGICAL RELEVANCE:

Ainsliaea fragrans Champ. (AFC) is a traditional Chinese medicine used for gynecological inflammations. However, its specific effects and molecular mechanisms in treating endometritis remain unclear.

AIM OF THE STUDY:

The primary objective of this work was to assess the protective effects of AFC in a murine model of LPS-induced endometritis and to decode the signaling pathways involved.

MATERIALS AND METHODS:

Mice with LPS-induced endometritis were given AFC (0.5, 1, 2 g/kg) or dexamethasone to assess its protective effects. Uterine pathological changes, inflammatory cytokine levels, and immune cell infiltration were assessed. Complementary transcriptomic and proteomic analyses were performed to identify key pathways, followed by in vitro validation in THP-1 cell using mitochondrial function assays, immunofluorescence, Western blotting, and co-immunoprecipitation.

RESULTS:

AFC significantly alleviated LPS-induced uterine swelling, diminished the levels of IL-1β and TNF-α, ameliorated histopathological damage, and decreased neutrophil and macrophage infiltration. Integrative omics analysis identified the cytosolic DNA-sensing and NOD-like receptor signaling pathways as core mechanisms. The anti-inflammatory mechanism of AFC involved multifaceted regulation of the STING-TBK1-IRF3 signaling and NLRP3 inflammasome pathways. On one hand, AFC maintained mitochondrial homeostasis by upregulating membrane potential, attenuating ROS overproduction, and blocking mtDNA escape into the cytosol, which in turn inactivated the STING-TBK1-IRF3 cascade. On the other hand, AFC reduced NLRP3 and cleaved Caspase-1 abundance, abrogated their interaction, and thus impeded NLRP3 inflammasome complex formation.

CONCLUSION:

AFC alleviates LPS-induced endometritis through the STING-TBK1-IRF3 signaling pathway and the NLRP3 inflammasome signaling pathway, representing a promising candidate drug with early-interventional or preventive potential.

4,974

项与地塞米松相关的新闻（医药）

2026-10-15

·药学进展

学科前沿 | 上海药物所合作设计纳米涂层乳糖颗粒，助力载体型吸入粉雾剂转化性能

“ 点击蓝字关注我们上海药物所合作设计纳米涂层乳糖颗粒，助力载体型吸入粉雾剂转化性能 PPS 吸入粉雾剂（DPIs）具有无需推进剂、制剂稳定、便于携带和使用等优势，是实现肺部及全身给药的重要技术平台。乳糖是目前应用最成熟的吸入粉雾剂载体，能够改善粉体流动性和剂量均一性，并促进微粉化药物在吸入过程中的分散。而药物与乳糖载体之间的相互作用需要保持适宜平衡：黏附过强阻碍药物从载体表面脱附，降低有效肺部沉积；黏附过弱则影响混合均匀性和剂量稳定性。因此，合理调控粉体体系的内聚-黏附平衡，是提升载体型DPIs递送效率的关键。 2026年8月3日，中国科学院上海药物研究所张继稳团队在国际学术期刊Advanced Science 发表研究论文“Nanometer Layer Coating to Lactose Particles for Optimization of Dexamethasone Pulmonary Delivery”，报道了一种纳米涂层（NLC）方法，以地塞米松（DEX）为模型药物，系统比较了固体混合、蒸气涂层、混悬液涂层和溶液涂层等乳糖表面改性方法。研究发现，以亮氨酸为表面改性剂，通过NLC法在乳糖颗粒表面形成连续、均一的纳米尺度涂层，显著降低药物-载体之间的黏附作用，在改善粉体流动性的同时，显著提高DEX的有效肺沉积。采用NLC法，亮氨酸用量仅为乳糖质量的0.05%时，即可获得优秀的制剂性能。采用纳米涂层乳糖制备的DEX吸入粉雾剂，其细粒子分数（FPF）由23%提高至50.15%，同时保持了良好的流动性。制剂在6个月储存后性能保持稳定，6批平行制备样品表现出较好的批间一致性。为揭示NLC的结构基础与作用机制，该研究构建了多尺度、表面敏感的先进表征体系。综合采用飞行时间二次离子质谱（TOF-SIMS）、同步辐射微区X射线衍射（SR-μXRD）、聚焦离子束扫描电镜（FIB-SEM）等技术，从化学组成与空间分布、晶相结构以及微观截面形貌等多个层面，对药物–载体界面及其微观结构进行了深入解析。结果显示，NLC并未发生明显改变乳糖颗粒的整体形貌，却使颗粒表面显著变得平滑，表面均方根粗糙度由938.7nm降至453.0nm。同时，DEX与乳糖之间的平均相互作用力由6.35nN降至4.30nN，表明NLC能够有效减弱药物黏附，最终改善吸入药物的空气动力学性能。亮氨酸在NLC乳糖表面分布更加均一、连续，并以高度分散、低结晶度或无定形状态存在。多种表征手段共同显示乳糖颗粒表面形成了纳米尺度的亮氨酸层。因此，亮氨酸NLC通过覆盖乳糖表面的高能黏附位点、填补部分表面凹槽，并降低药物与载体之间的有效接触面积和机械嵌合作用，从而减弱界面黏附，促进药物在吸入气流作用下从载体表面脱附，最终改善吸入药物的空气动力学性能。体内研究进一步验证了该策略的递送优势。与传统乳糖载体制剂相比，吸入DEX-NLC-LA后，DEX血浆暴露量明显增加，AUC由442.9ng/mL·h提高至613.6ng/mL·h，提高1.5倍。在高海拔急性肺损伤大鼠模型中，吸入0.1mg/kg和0.3mg/kg的DEX-NLC-LA均能够明显减轻肺组织损伤、肺水肿及炎症反应。尤其是吸入0.1mg/kg即可产生明显治疗效果，相较于3mg/kg静脉注射地塞米松，仅需约1/30的剂量。该研究围绕载体型吸入粉体的内聚-黏附平衡，建立了一种用量低、工艺简便且重复性较好的纳米涂层技术修饰乳糖表面。审稿人高度评价该研究通过多尺度先进表征体系深入解析药物-载体界面机制，突破了传统经验处方优化的局限，为提升DPIs开发效率提供了科学依据。上海药物所与沈阳药科大学联合培养研究生聂芩（博士）、刘佳贺（硕士）为该文的共同第一作者。上海药物所张继稳研究员、王彩芬博士和伍丽副研究员为该文的共同通讯作者。文章来源：中科院上海药物研究所美编排版：朱玲欣文章审核：王子怡朱玲欣罗琪【免责声明】以上内容来源于互联网，不代表本平台立场或观点；如有侵犯作者著作权，请及时与我们联系（Tel：025-83271227，或直接在微信平台留言），我们将及时更正或删除。《药学进展》杂志由教育部主管、中国药科大学主办，中国科技核心期刊（中国科技论文统计源期刊）。刊物以反映药学科研领域的新方法、新成果、新进展、新趋势为宗旨，以综述、评述、行业发展报告为特色，以药学学科进展、技术进展、新药研发各环节技术信息为重点，是一本专注于医药科技前沿与产业动态的专业媒体。《药学进展》注重内容策划、加强组稿约稿、深度挖掘、分析药学信息资源、在药学学科进展、科研思路方法、靶点机制探讨、新药研发报告、临床用药分析、国际医药前沿等方面初具特色；特别是医药信息内容以科学前沿与国家战略需求相合，更加突出前瞻性、权威性、时效性、新颖性、系统性、实战性。根据最新统计数据，刊物篇均下载率连续三年蝉联我国医药期刊榜首，复合影响因子1.311，具有较高的影响力。《药学进展》编委会由国家重大专项化学药总师陈凯先院士担任主编，编委由新药研发技术链政府监管部门、高校科研院所、制药企业、临床医院、CRO、金融资本及知识产权相关机构近两百位极具影响力的专家组成。联系《药学进展》↓↓↓ 编辑部官网：pps.cpu.edu.cn；邮箱：yxjz@163.com；电话：025-83271227。欢迎投稿、订阅！往期推荐聚焦“第七届药学前沿学术论坛暨《药学进展》编委会会议” 聚力前沿赛道，共启学术新程：第七届药学前沿学术论坛在南京隆重启幕承学术匠心，启时代新章：《药学进展》第七届编委会、第三届青年编委会成立大会在宁召开聚焦“兴药为民·2023生物医药创新融合发展大会”“兴药为民·2023生物医药创新融合发展大会”盛大启幕！院士专家齐聚杭城，绘就生物医药前沿赛道新蓝图“兴药强刊”青年学者论坛暨《药学进展》第二届青年编委会议成功召开“兴药为民·2023生物医药创新融合发展大会”路演专场圆满收官！校企合作新旅程已启航我知道你在看哟

2026-10-15

·BioSpace

Eclipse Life Sciences Announces Positive Topline Results from Phase 2 BETTIS-1 Study Evaluating EC-104 for Diabetic Macular Edema (DME)

RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eclipse Life Sciences, Inc. , a privately held clinical-stage biopharmaceutical company developing next-generation therapies for retinal diseases, today announced positive topline results from its BETTIS-1 Phase 2 clinical trial comparing EC-104 fluocinolone acetonide (FA) extended release versus Ozurdex® for the treatment of diabetic macular edema (DME). EC-104 is a novel, completely biodegradable intravitreal corticosteroid implant engineered to deliver approximately six months of durable drug release. The BETTIS‑1 trial met its primary endpoint, demonstrating a favorable safety pro both EC-104 formulations compared to Ozurdex®. Secondary endpoints showed superior clinically meaningful and durable improvement in both best corrected visual acuity and OCT central subfield thickness at 24 weeks, when compared to Ozurdex®. The superiority of EC-104 was demonstrated in a study population of subjects with a previous suboptimal response to anti-VEGF therapy, which represents a significant unmet need and commercial opportunity. “These results position EC-104 as a highly competitive candidate in the DME landscape,” said Scott Cousins, MD, CEO and VP for Research and Development at Eclipse Life Sciences . “The six-month durability, consistent anatomical response, and strong safety pro EC-104’s potential to meaningfully reduce treatment burden. EC-104 continues to show promise as a differentiated corticosteroid option for patients who need longer lasting treatment. We believe these data support advancement into Phase 3 and create a compelling opportunity for strategic collaboration.” Phase 2 BETTIS-1 Topline Findings Primary Endpoint Achieved: EC-104 demonstrated a favorable safety pro low rates of treatment-related adverse events and no unexpected safety signals. Durable Anatomical Response: Both EC-104 formulation groups showed sustained reductions in central subfield thickness (CST) through 24 weeks, consistent with the implant’s six-month release profile. Clinical Benefit in Anti-VEGF-Resistant Subjects: Subjects with documented suboptimal response to prior anti-VEGF therapy exhibited clinically meaningful anatomical improvements, reinforcing EC-104’s potential role as an alternative treatment. Intraocular Pressure (IOP) Profile: Patients with prior corticosteroid tolerance maintained acceptable IOP outcomes in both formulation arms. “These results highlight the potential of EC-104 to reduce treatment burden for patients who struggle with frequent injections and insufficient response to anti-VEGF therapies,” said Victor H. Gonzalez, MD , retina specialist and Founder, Gulf Coast Eye Institute in McAllen, Texas. “An authentic six-month sustained release intravitreal corticosteroid option will be a significant advancement for this population.” Strategic Opportunity With strong Phase 2 data and a well-defined path for late-stage clinical development, regulatory approval and commercialization, Eclipse Life Sciences is exploring partnership opportunities to accelerate Phase 3 initiation and global commercialization. EC-104’s pro it as a differentiated entrant in the multi-billion-dollar DME market where durability and efficacy drive adoption. Next Steps Eclipse Life Sciences plans to engage with regulatory authorities to discuss Phase 3 development of EC-104 and expects to initiate a pivotal program in 2027. Full BETTIS-1 data will be presented at an upcoming ophthalmology conference and will be submitted for publication in a peer-reviewed journal. About Diabetic Macular Edema (DME) DME is the leading cause of vision loss among working-age adults. Although standard of care is initiating treatment with anti-VEGF therapies, many patients experience suboptimal response and require alternative treatments. Intravitreal corticosteroids play a critical role in addressing neuroinflammatory pathways in DME. About Eclipse Life Sciences, Inc. Eclipse Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic diseases. In addition to EC-104, Eclipse is advancing EC-303 for intermediate dry age-related macular degeneration (AMD) and EC-501, a six-month anti-VEGF therapy candidate for wet AMD, DME, and macular edema following retinal vein occlusion (RVO). Investigational product. Not approved by regulatory authorities. For media inquiries: info@eclipselifesciences.com Forward Looking Statements: This press release contains forward looking statements. Actual results may differ materially from those expressed or implied by such statements. Factors that could cause actual results to differ include clinical trial outcomes, regulatory decisions, and market conditions.

临床结果临床2期

2026-10-14

·乳爱之生

乳腺癌脑转移：不必谈之色变，读懂诊断与治疗

点击下方关注，乳腺癌知识不错过~ 作者：如是很多乳腺癌患者听到“脑转移”就十分恐慌。近些年，乳腺癌脑转移正在变多，一方面是乳腺癌整体治疗水平提升，患者生存期变长；另一方面，磁共振等影像技术进步，很多没有明显不适的微小脑转移也能够被查出来。如今治疗手段越来越丰富，通过局部治疗搭配全身药物治疗，可以控制脑部病灶、缓解神经不适、保护大脑认知功能，改善生活质量，尽可能延长生存时间。如今针对脑转移的治疗手段已日益丰富，通过局部治疗联合全身药物治疗，大多可以有效控制颅内病灶、缓解神经系统相关症状、保护大脑认知功能，在保障生活质量的前提下，尽可能延长患者生存时间。很多患者会困惑：发生脑转移后该怎么办？要不要做手术、做放疗？会不会治疗之后损伤大脑、记忆力下降？下面我们就通俗讲讲乳腺癌脑转移的相关知识。 1 哪些乳腺癌更容易发生脑转移？脑部转移会出现在什么位置？脑转移分为脑实质转移和脑膜转移两大类，绝大多数为脑实质转移，脑膜转移发生率约 6.9%。脑实质转移80%出现在大脑半球，15%发生在小脑，仅有5%出现在脑干。脑实质合并脑膜转移很少见，仅 3.6%，但这类患者预后最差。不同乳腺癌亚型，脑转移风险差别较大。 HER2阳性、三阴性乳腺癌发生脑转移的风险较高。在转移性疾病病程当中，HR‑/HER2+、三阴性乳腺癌脑转移发生率超过 11%；HR+/HER2‑脑转移风险相对较低。 2 出现这些症状，要警惕脑转移！脑转移的表现和肿瘤长在大脑哪个位置密切相关，主要分为三类症状： 1. 颅内压升高相关症状：头痛、恶心、呕吐。肿瘤占位、脑组织水肿、脑脊液循环不通畅，都会升高颅内压力。情况严重时甚至会诱发脑疝，危及生命。 2. 神经功能缺损：肢体偏瘫、视力改变。肿瘤破坏脑组织，造成运动、感觉、视力受损，会严重影响日常生活。 3. 刺激性症状：癫痫、幻视。癫痫发作风险很高，癫痫持续发作会造成全身多器官损伤，属于需要警惕的危险情况。 ⚠️提示：部分脑转移的早期阶段可以完全没有症状，不能只靠身体感受判断。 3 如何确诊脑转移？ 1. 头颅增强磁共振（增强 MRI）是诊断脑实质转移的金标准。它比 CT 更容易发现很小的病灶以及脑膜转移。如果身体条件无法做磁共振，可以选择增强 CT 作为替代。 2. PET‑CT。 PET/CT可以发现身体其他部位的肿瘤，但对脑内的小转移灶不太敏感，所以不能完全替代磁共振或CT。 3. 腰穿（腰椎穿刺）：如果影像高度怀疑脑膜转移，需要抽取脑脊液化验进一步确诊。单纯脑实质转移一般不需要腰穿，只有颅内高压需要减压分流时才考虑。 4 乳腺癌脑转移治疗原则是什么？脑转移治疗需要神经外科、放疗科、肿瘤内科、姑息治疗团队一起评估。医生会综合两方面情况考虑治疗。 ✅患者情况：有没有神经症状、体力状态、年龄、基础疾病、个人治疗意愿。 ✅肿瘤情况：脑转移病灶数目、大小、位置、颅外肿瘤是否可控、乳腺癌分子分型。治疗目标是控制脑部病灶、缓解神经症状、保护记忆力等认知功能、提高生活质量、延长生存。脑转移治疗分为局部治疗、全身药物治疗、对症支持治疗三大类。 5 脑转移局部治疗：手术、精准放疗、全脑放疗，分别适合哪些特征的患者？ 1. 外科手术。适合单发、体积较大、伴随明显神经症状，颅外肿瘤控制稳定的患者。 2. 立体定向放射外科 SRS/SRT，属于精准放疗，集中射线打击肿瘤，最大程度保护周边正常脑组织。适合：转移灶≤4个、病灶偏小，不适合接受手术的患者；可单独使用，也可联合其他治疗手段。 3. 全脑放疗（WBRT）适合：颅内广泛多发转移灶的患者。海马区负责人的记忆、空间定位。传统全脑放疗容易损伤海马，造成记忆力减退。海马保护全脑放疗依靠精准技术，减少海马组织接受的辐射剂量；联合神经保护药物美金刚，在不降低抗肿瘤疗效的前提下，可以把认知功能下降的发生风险降低 24%。无论选择哪一种局部治疗，都需要配合全身药物治疗，控制全身肿瘤，降低颅内新发转移风险。 6 全身药物治疗：不同亚型，用药方案大不相同随着新药研发进展，不少靶向药物、ADC 药物可以穿透血‑脑屏障，实现对颅内肿瘤的抑制，不同亚型的选择各有侧重。 1 HER2 阳性乳腺癌脑转移多款透过血脑屏障的靶向药物疗效明确，临床指南重点推荐以下方案： 1). 吡咯替尼+卡培他滨：这个方案针对尚未放疗、病情稳定的脑转移，颅内客观缓解率可达 44%，中位缓解持续时间12.5个月；对于放疗后颅内进展的病灶，也具备一定疗效，中位缓解时间7.7个月。 2). 图卡替尼+曲妥珠单抗+卡培他滨：这个方案对经治疗后处于稳定的脑转移，中位缓解持续时间 13.9 个月；针对局部治疗后进展的脑转移，客观缓解率 47%，显著降低脑转移进展及死亡风险。（注：图卡替尼国内暂未上市）。 3). 德曲妥珠单抗（DS‑8201，T-DXd）：多项研究证实它的颅内抗肿瘤效果优异，对脑转移，中位有效控制时间可达15个月，明显降低疾病进展与死亡风险。 2 三阴性乳腺癌脑转移没有特别推荐，可以考虑化疗联合贝伐珠单抗，或者联合免疫治疗，以及ADC。贝伐珠单抗可以减轻肿瘤周围严重的脑水肿。肿瘤会分泌因子让脑组织水肿，引发剧烈头痛呕吐，激素、甘露醇效果不好的时候，贝伐珠单抗能够减轻水肿，也可以处理放疗之后出现的脑组织水肿损伤。贝伐联合化疗也可以获得不错的颅内病灶缓解。联合依托泊苷和顺铂治疗全脑放疗后的乳腺癌脑转移，77%患者颅内病灶明显缩小，中位有效控制时间为6.1个月。贝伐珠单抗联合优替德隆，颅内客观缓解率为55%，中位有效控制时间达8.4个月。抗体偶联药物（ADC）。德曲妥珠单抗对 HER2 阳性、HER2 低表达脑转移均显示出治疗获益；戈沙妥珠单抗（TROP‑2 ADC）在包括脑转移在内的三阴性乳腺癌人群中，可显著延长无进展生存期。 gBRCA 基因突变，可以选择奥拉帕利，他拉唑帕尼等抑制剂，临床试验提示能够延长脑转移患者无进展生存。 3 HR+HER2-乳腺癌脑转移内分泌治疗脑转移的证据还不算充分。研究表明：内分泌治疗联合阿贝西利，24%患者获得疾病稳定。ADC药物T‑Dxd 用于HER2低表达人群，颅内疾病控制中位时间 6.9‑11.9个月；Dato‑Dxd 针对Trop‑2，30%患者获得肿瘤的显著缩小。脑转移可以考虑内分泌联合方案，一旦病情快速进展、神经功能快速变差，优先选择透脑效果好的化疗，或是有中枢活性的新型 ADC 药物来控制肿瘤。 4 脑膜转移的药物治疗 1). HER2 阳性脑膜转移。抗 HER2 靶向仍是核心。图卡替尼三药联合、奈拉替尼联合卡培他滨、吡咯替尼联合节拍化疗均可带来临床获益；德曲妥珠单抗可使77.8% 患者颅内病灶明显缩小。放疗还可一定程度开放血脑屏障，进一步提升药物疗效。 2). 三阴性脑膜转移：可选方案包括大剂量甲氨蝶呤化疗、抗血管生成联合化疗、免疫治疗、ADC 新药等。 3). 鞘内注射治疗：直接将药物注入脑脊液，作用于脑膜病灶，可用药物包括甲氨蝶呤、脂质体阿糖胞苷、曲妥珠单抗等。全身治疗联合鞘内给药，有助于延长病灶控制时间。 7 对症支持治疗，不可忽视脑转移带来的各类不适会严重影响生活质量，对症处理是全程管理重要一环： 1. 降颅压、消水肿：甘露醇、甘油果糖、呋塞米脱水；地塞米松减轻脑水肿。注意：激素仅缓解水肿症状，不能杀灭肿瘤，不改善长期生存。 2. 抗癫痫治疗：不推荐预防性用药，仅发生癫痫之后才启动抗癫痫药物。 3. 止痛对症：规范止痛，改善痛苦体验。 4.放疗后康复照护：针对放疗后乏力、恶心、食欲下降，做好营养支持，适度活动，维持电解质平衡，预防长期卧床带来的感染等并发症 8 写在最后脑转移听上去很可怕，但如今已经有越来越多的“武器”对抗它。无论是外科手术、精准放疗，还是可以作用于脑部的靶向药、ADC 药物，再加上对症支持缓解病痛。医生会结合你的肿瘤分型、病灶情况、身体状态，量身定制方案。面对脑转移不必过度绝望，积极规范就医，争取更好的生活质量与生存时间。免责声明：本文内容基于公开发表的指南和研究数据，旨在科普分享，不能替代专业医疗建议。所有治疗决策请遵从您的主治医师指导。图片来源：包图网参考文献 1. Corti, C., et al. Cancer Treatment Reviews, 2022. 103: p. 102324 2. Tao Wang, et al. TBCR, 2022;3:22； 3. Bernardo Cacho-Díaz, et al. Curr Probl Cancer. 2019 Aug;43(4):312-323. 4. Lamba, N., et, al. Neuro-oncology, 2021. 23(9): p. 1447-1456 5. Rostami R, et al. J Neurooncol 2016; 127:407–414. 6. Chen E, et al. J Radiat Oncol 2012; 1:179–186. 7. 中国临床肿瘤学会乳腺癌诊疗指南（2025年版） 8. 中国抗癌协会中华医学会肿瘤学分会乳腺癌诊疗指南与规范（2026年版） 9. Ramakrishna N, et al. J Clin Oncol 2022; 40:2636–2655. 10. E Le Rhun, et al. Ann Oncol. 2021 Nov;32(11):1332-1347. 11. NCCN 2021.v2.: Central Nervous System Cancers. 12. Lin NU. Ecancermedicalscience 2013; 7:307 13. Bartolotti M, et al. Future Oncol 2013; 9:1653–1664; 14. Kaal EC & Vecht CJ. CNS Drugs 2007; 21:559–579; 15. Soon YY, et al. Cochrane Database Syst Rev 2014; CD009454 16. Brown, P.D., et al., Lancet Oncol, 2017. 18(8): p. 1049-1060 17. Brown, P.D., et al.,. J Clin Oncol, 2020. 38(10): p. 1019-1029. 18. Lancet Oncol 2022; 23: 353–61 19. N Engl J Med 2020;382:597-609. 20. J Clin Oncol 38:2610-2619. © 2020 21. N Engl J Med 2022;386:1143-54 22. Lancet 2023; 401: 105–17 23. Cancer Biol Ther. 2018; 19(6): 461–464 24. J Neurooncol. 2014 Sep;119(2):369-76 25. Yen-Shen Lu，et al. Clin Cancer Res. 2015 Apr 15;21(8):1851-8. 26. 曹晓珊，等人.三阴性乳腺癌脑转移治疗的研究进展. CHINA ONCOLOGY 2024,8:777-784 27. Tung NM et al. Presentation relating to abstract 1052,2018 ASCO. Litton J et al. Presentation relating to abstract GS6-07, 2017 SABCS 与癌共舞公众号及网站及APP上发表的文章及讨论仅代表作者或发帖人个人观点，不代表平台立场。与癌共舞公众号文章经医学编辑和版主审核，具有明显谬误和不良引导的文章将禁止发表。星标关注，精彩内容不错过！

100 项与地塞米松相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00292	地塞米松	D07AB19 H02AB02 D10AA03	DB01234

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
黄斑水肿	美国	AbbVie, Inc.	2026-03-11
非感染性后葡萄膜炎	美国	AbbVie, Inc.	2026-03-11
免疫球蛋白轻链淀粉样变性	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2021-08-25
免疫球蛋白轻链淀粉样变性	日本	Sandoz KK	2021-08-25
眼部炎症	美国	Ocular Therapeutix, Inc.	2018-11-30
眼科外科手术	美国	Ocular Therapeutix, Inc.	2018-11-30
术后炎症	美国	EyePoint Pharmaceuticals US, Inc.	2018-02-09
术后炎症	美国	EyePoint, Inc.	2018-02-09
糖尿病性黄斑水肿	欧盟	AbbVie Deutschland GmbH & Co. KG	2010-07-26
糖尿病性黄斑水肿	冰岛	AbbVie Deutschland GmbH & Co. KG	2010-07-26
糖尿病性黄斑水肿	列支敦士登	AbbVie Deutschland GmbH & Co. KG	2010-07-26
糖尿病性黄斑水肿	挪威	AbbVie Deutschland GmbH & Co. KG	2010-07-26
视网膜静脉阻塞相关黄斑水肿	欧盟	AbbVie Deutschland GmbH & Co. KG	2010-07-26
视网膜静脉阻塞相关黄斑水肿	冰岛	AbbVie Deutschland GmbH & Co. KG	2010-07-26
视网膜静脉阻塞相关黄斑水肿	列支敦士登	AbbVie Deutschland GmbH & Co. KG	2010-07-26
视网膜静脉阻塞相关黄斑水肿	挪威	AbbVie Deutschland GmbH & Co. KG	2010-07-26
后葡萄膜炎	欧盟	AbbVie Deutschland GmbH & Co. KG	2010-07-26
后葡萄膜炎	冰岛	AbbVie Deutschland GmbH & Co. KG	2010-07-26
后葡萄膜炎	列支敦士登	AbbVie Deutschland GmbH & Co. KG	2010-07-26
后葡萄膜炎	挪威	AbbVie Deutschland GmbH & Co. KG	2010-07-26

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
术后疼痛	申请上市	新加坡	上海蔼睦医疗科技有限公司	2024-02-19
疼痛	临床3期	中国	Ocular Therapeutix, Inc.	2023-08-17
疼痛	临床3期	中国	上海蔼睦医疗科技有限公司	2023-08-17
葡萄膜炎	临床3期	中国	欧康维视生物医药（上海）有限公司	2022-08-22
视网膜炎	临床3期	美国	AbbVie, Inc.	2021-10-12
青光眼	临床3期	-	Ocular Therapeutix, Inc.	2020-11-01
开角型青光眼	临床3期	-	Ocular Therapeutix, Inc.	2020-11-01
浆细胞瘤	临床3期	美国	Millennium Pharmaceuticals, Inc.	2016-11-29
梅尼埃病	临床3期	美国	Otonomy, Inc.	2015-10-27
眼睛疼痛	临床3期	-	Ocular Therapeutix, Inc.	2014-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01745588 (CTgov)	临床2期	难治性多发性骨髓瘤	23	stem cell+Pomalidomide+Clarithromycin (Clarithromycin + Pomalidomide + Dexamethasone + Stem Cell)	艱衊顧鏇膚鏇鏇繭窪窪 = 鏇積鑰遞鏇艱鹽廠襯壓襯鹽蓋簾製顧顧鬱製襯 (範顧憲鏇構齋齋鏇製鬱, 鹽糧觸顧構窪鑰醖構鬱 ~ 積艱糧膚顧積糧觸衊艱) 更多	-	2026-09-25
				Pomalidomide+Clarithromycin+Dexamethasone (Clarithromycin + Pomalidomide + Dexamethasone Alone)	艱衊顧鏇膚鏇鏇繭窪窪 = 鑰鏇艱選淵窪顧衊艱鹽襯鹽蓋簾製顧顧鬱製襯 (範顧憲鏇構齋齋鏇製鬱, 膚醖簾鏇夢顧製選網製 ~ 鑰壓獵衊廠鬱壓淵鏇範) 更多
NCT04484623 (DREAMM-8, IMS2026)	临床3期	复发性多发性骨髓瘤	302	Belantamab Mafodotin+Pomalidomide+Dexamethasone	壓獵鏇簾築蓋衊觸範膚(餘遞壓蓋艱繭襯糧餘積) = 壓構廠鹹醖艱顧夢窪構願鏇鏇醖齋簾觸範範鹹 (膚蓋齋鏇簾製網壓遞積 )	积极	2026-09-23
				Pomalidomide+Bortezomib+Dexamethasone	壓獵鏇簾築蓋衊觸範膚(餘遞壓蓋艱繭襯糧餘積) = 鏇壓餘鹹鹽夢選範選獵願鏇鏇醖齋簾觸範範鹹 (膚蓋齋鏇簾製網壓遞積 )
NCT04484623 (DREAMM-8, IMS2026)	临床3期	多发性骨髓瘤二线	159	Belantamab Mafodotin, Pomalidomide, and Dexamethasone (BPd)	鏇廠遞繭繭鑰獵鬱積願(範憲鬱夢鑰衊醖鏇襯廠) = 膚範鏇築憲艱廠壓蓋廠鑰餘範鹽築觸簾網襯膚 (齋遞簾繭鑰顧衊顧糧遞 ) 更多	积极	2026-09-23
				Pomalidomide, Bortezomib, and Dexamethasone (PVd)	鏇廠遞繭繭鑰獵鬱積願(範憲鬱夢鑰衊醖鏇襯廠) = 範築衊觸構糧壓壓壓範鑰餘範鹽築觸簾網襯膚 (齋遞簾繭鑰顧衊顧糧遞 ) 更多
NCT05590923 (CTgov)	临床4期	化疗引起的恶心和呕吐 \| 恶心 \| 呕吐	23	DEX (Dexamethasone) (DEX (Dexamethasone))	蓋襯糧膚衊觸繭廠壓簾 = 構網鑰齋淵艱餘餘壓築網鹽窪鹽簾遞鏇壓窪蓋 (築淵網壓齋窪蓋夢鹹築, 顧壓膚鹽願製鬱鏇積顧 ~ 蓋鑰餘憲獵願蓋鑰鑰餘) 更多	-	2026-09-02
				OLA (Olanzapine) (OLA (Olanzapine))	蓋襯糧膚衊觸繭廠壓簾 = 蓋簾築糧齋簾簾鹹觸鏇網鹽窪鹽簾遞鏇壓窪蓋 (築淵網壓齋窪蓋夢鹹築, 壓構鏇獵鏇艱餘鏇簾餘 ~ 鑰艱窪製膚網範願糧鏇) 更多
NCT05018091 (CTgov)	临床4期	-	438	Dexamethasone 4mg (Group 1)	餘願範鹹願築鹹構膚醖(膚觸廠製蓋衊獵糧鏇艱) = 鹽淵鏇遞壓築鏇鏇繭繭鑰襯築選鬱鹽鏇選糧鬱 (齋窪遞齋壓築糧願築鬱, 168.9) 更多	-	2026-08-03
				Dexamethasone 8 Mg/mL Injectable Suspension (Group 2)	餘願範鹹願築鹹構膚醖(膚觸廠製蓋衊獵糧鏇艱) = 鏇顧艱選夢膚夢夢壓憲鑰襯築選鬱鹽鏇選糧鬱 (齋窪遞齋壓築糧願築鬱, 122.3) 更多
NCT06128369 (OPTIMIZE-2, CTgov)	临床3期	眼睛疼痛 \| 眼部炎症 \| 黄斑水肿 ... 更多	117	OCS-01 (OCS-01)	蓋網構鹽窪廠鬱壓襯鏇 = 網窪鏇顧鹽襯鏇獵鏇願餘積廠網製遞膚鹹簾憲 (醖顧憲製窪遞窪顧醖廠, 艱鹹遞壓簾觸憲鹽鑰壓 ~ 鑰構網繭觸廠鬱鹽窪觸) 更多	-	2026-07-30
				Vehicle (Vehicle)	蓋網構鹽窪廠鬱壓襯鏇 = 鬱觸獵遞餘壓鑰憲遞鹹餘積廠網製遞膚鹹簾憲 (醖顧憲製窪遞窪顧醖廠, 醖構鑰醖艱壓製獵憲膚 ~ 鏇獵夢憲鏇窪夢壓鹽膚) 更多
NCT02516423 (CTgov)	临床3期	浆细胞瘤	11	Lenalidomide+ixazomib+zoledronic acid+dexamethasone (Ixazomib + Lenalidomide + Dexamethasone + Zoledronic Acid)	餘憲衊襯糧廠齋壓鹽壓 = 鬱齋艱衊膚糧窪獵選構蓋齋襯顧積鏇鬱膚窪膚 (鑰鑰鹽願糧獵廠範遞製, 繭淵遞鬱觸衊艱艱鹽鬱 ~ 糧構憲繭選鹹築範憲鹹) 更多	-	2026-06-30
				zoledronic acid (Zoledronic Acid)	餘憲衊襯糧廠齋壓鹽壓 = 艱鹹範製餘膚範獵醖襯蓋齋襯顧積鏇鬱膚窪膚 (鑰鑰鹽願糧獵廠範遞製, 鬱鹹築襯選願繭範襯艱 ~ 淵壓窪網糧淵築壓壓夢) 更多
NCT07150104 (CTgov)	临床1/2期	多发性骨髓瘤	14	Mafodotin+Nirogacestat+Pomalidomide+Dexamethasone+Belantamab	餘範鏇繭鑰廠選窪遞鑰 = 窪蓋遞廠醖餘糧範餘網繭範網蓋廠衊鏇獵廠願 (觸築艱選簾簾壓製構夢, 願鹽獵夢築繭憲淵膚壓 ~ 鏇淵顧繭鬱製鏇簾壓壓) 更多	-	2026-06-25
NCT07150091 (CTgov)	临床1/2期	多发性骨髓瘤	20	Mafodotin+Lenalidomide+Nirogacestat+Dexamethasone+Belantamab (0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone)	憲製繭顧範壓獵積衊憲 = 網鑰鬱蓋蓋膚鹹製鬱艱鏇遞觸窪願鹽蓋範鹽襯 (選鬱淵鹹鏇齋壓廠鏇餘, 鑰顧蓋鬱壓構願壓襯襯 ~ 憲積積膚獵醖築網遞觸) 更多	-	2026-06-16
				Mafodotin+Lenalidomide+Nirogacestat+Dexamethasone+Belantamab (1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone)	憲製繭顧範壓獵積衊憲 = 膚遞範網淵觸獵膚餘遞鏇遞觸窪願鹽蓋範鹽襯 (選鬱淵鹹鏇齋壓廠鏇餘, 鑰願築膚範顧餘廠鏇壓 ~ 積鹹淵鬱築遞獵鑰醖糧) 更多
NCT05552976 (SUCCESSOR-2, EHA2026)	临床3期	复发性多发性骨髓瘤	479	Mezigdomide 1.0 mg + Kd	壓鬱鹽糧獵製鏇築窪壓(醖憲構範蓋膚襯壓醖艱) = 繭顧鹹壓築蓋廠齋淵觸顧壓鹹蓋憲遞顧膚網獵 (願壓構繭網願遞鏇積夢 ) 更多	积极	2026-06-02
				Kd	壓鬱鹽糧獵製鏇築窪壓(醖憲構範蓋膚襯壓醖艱) = 積窪獵憲獵願構積膚淵顧壓鹹蓋憲遞顧膚網獵 (願壓構繭網願遞鏇積夢 ) 更多